Compare FTK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTK | ABUS |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 924.7M | 1.0B |
| IPO Year | 1997 | 2008 |
| Metric | FTK | ABUS |
|---|---|---|
| Price | $24.04 | $5.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $20.00 | $5.00 |
| AVG Volume (30 Days) | 670.7K | ★ 4.2M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.06 | 55.26 |
| EPS | 0.38 | ★ 0.84 |
| Revenue | ★ $136,092,000.00 | $14,083,000.00 |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $16.38 | $239.71 |
| P/E Ratio | $61.95 | ★ $6.14 |
| Revenue Growth | ★ 214.53 | 128.21 |
| 52 Week Low | $11.43 | $3.50 |
| 52 Week High | $39.67 | $5.45 |
| Indicator | FTK | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 61.60 |
| Support Level | $15.27 | $4.99 |
| Resistance Level | $25.39 | $5.42 |
| Average True Range (ATR) | 1.32 | 0.14 |
| MACD | -0.41 | -0.00 |
| Stochastic Oscillator | 19.61 | 54.23 |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.